Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

Core Viewpoint - Virax Biolabs Group Limited has appointed Dr. Iain Miller as an Independent Director to its Board, effective July 29, 2025, succeeding Yair Erez, who is stepping down to pursue other professional opportunities [1][2]. Group 1: Appointment Details - Dr. Miller brings over 30 years of leadership experience in the diagnostics and MedTech sectors, having held senior positions at GE Healthcare, bioMérieux, and Massachusetts General Hospital [3]. - He has founded and led four MedTech companies, including Presymptom Health, where he developed InfectiClear®, a novel diagnostic for infectious diseases [3][4]. - Dr. Miller holds a PhD in BioEngineering, an MBA, and a BSc in Physics & Electronics, and has published extensively on diagnostic innovation [4]. Group 2: Strategic Importance - The CEO of Virax, James Foster, emphasized that Dr. Miller's leadership and expertise will be crucial as the company advances its immune profiling platform and progresses towards IVD development and market entry [5]. - Dr. Miller expressed excitement about joining Virax at a time of strategic focus, highlighting the potential of the immune profiling platform to enhance monitoring of chronic and post-viral conditions [5]. Group 3: Company Focus - Virax Biolabs is focused on the detection of immune responses and diagnosis of viral diseases, currently developing T-Cell-based test technologies aimed at providing an immunology profiling platform [6]. - The company’s T-Cell testing is particularly relevant for diagnosing post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation [6].